NGL Fine Chem

Why is NGL Fine Chem Ltd falling/rising?

As of 04-Aug, NGL Fine Chem Ltd's stock price is rising, currently at 3,293.90, reflecting a year-to-date surge of 133.78% and strong investor interest, evidenced by a 162.37% increase in delivery volume. The stock is trading near its 52-week high and has consistently outperformed the Sensex and its sector.

As of 04-Aug, NGL Fine Chem Ltd's stock price is rising, currently at 3,293.90, with a change of 13.3 (0.41%) upwards. This upward movement can be attributed to several factors. Over the past week, the stock has increased by 2.47%, outperforming the Sensex, which rose by 2.17%. In the last month, NGL Fine Chem has shown a notable gain of 3.56%, compared to the Sensex's modest increase of 0.86%. Year-to-date, the stock has surged by an impressive 133.78%, while the Sensex has declined by 7.97%. Over the past year, the stock has risen by 156.35%, contrasting sharply with the Sensex's decrease of 3.20%.<BR><BR>Additionally, the stock is currently trading close to its 52-week high, being only 4.29% away from the peak of Rs 3,435.3. It has also outperformed its sector by 0.46% today and has experienced consecutive gains over the last two days, with a total return of 0.89% during this period. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Moreover, there has been a significant increase in investor participation, with delivery volume on August 3 rising by 162.37% compared to the 5-day average. This heightened interest suggests a growing confidence among investors in NGL Fine Chem Ltd, contributing to the stock's upward trajectory. Overall, these factors collectively explain the rise in NGL Fine Chem Ltd's stock price.

Which are the latest news on NGL Fine Chem?

Should I buy, sell or hold NGL Fine Chem Ltd?

How big is NGL Fine Chem?

As of 10th June, NGL Fine Chem Ltd has a market capitalization of 1,757.00 Cr, with recent net sales of 501.19 Cr and a net profit of 48.05 Cr.

As of 10th June, NGL Fine Chem Ltd has a market capitalization of 1,757.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, NGL Fine Chem reported Net Sales of 501.19 Cr and a Net Profit of 48.05 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 282.43 Cr and Total Assets of 433.39 Cr.

Who are in the management team of NGL Fine Chem?

The management team of NGL Fine Chem includes Rahul J Nachane (Managing Director), Rajesh N Lawande (Whole Time Director & CFO), Milind V Shinde (Chairman & Independent Director), Ajita Nachane (Non-Executive Director), Jayaram Sitaram (Independent Director), Pallavi Pednekar (Company Secretary), and Sarala Menon (Independent Director).

The management team of NGL Fine Chem includes the following key individuals:<BR><BR>1. **Rahul J Nachane** - Managing Director<BR>2. **Rajesh N Lawande** - Whole Time Director & CFO<BR>3. **Milind V Shinde** - Chairman & Independent Director<BR>4. **Ajita Nachane** - Non-Executive & Non-Independent Director<BR>5. **Jayaram Sitaram** - Non-Executive & Independent Director<BR>6. **Pallavi Pednekar** - Company Secretary & Compliance Officer<BR>7. **Sarala Menon** - Independent Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

Who are the peers of the NGL Fine Chem?

NGL Fine Chem's peers include Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, Hester Bios, Windlas Biotech, Amrutanjan Healt, Ind-Swift Labs, and Sakar Healthcare. In terms of performance, NGL Fine Chem has a 1-year return of 161.05%, while its management risk and growth are rated as average.

Peers: The peers of NGL Fine Chem are Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, Hester Bios, Windlas Biotech, Amrutanjan Healt, Ind-Swift Labs., and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kwality Pharma, Venus Remedies, Windlas Biotech, and Amrutanjan Healt, while Average management risk is found at Hikal, Indoco Remedies, NGL Fine Chem, Hester Bios, Sakar Healthcare, and the rest. Growth is rated as Good for Venus Remedies, while Below Average growth is noted for Kwality Pharma, Hikal, Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, and the rest. In terms of Capital Structure, Excellent ratings are given to Kwality Pharma, Venus Remedies, NGL Fine Chem, Windlas Biotech, and Amrutanjan Healt, while Below Average ratings are assigned to Hikal, Indoco Remedies, Hester Bios, Ind-Swift Labs., and the rest.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 268.68%, while Hikal has the lowest at -52.29%. NGL Fine Chem's 1-year return of 161.05% is significantly positive in comparison. Additionally, Hikal, Windlas Biotech, Amrutanjan Healt, and Sakar Healthcare have negative six-month returns.

What does NGL Fine Chem do?

NGL Fine-Chem Limited is a manufacturer of pharmaceuticals and intermediates for veterinary and human health, categorized as a Micro Cap company with a market cap of INR 1,757 Cr. As of March 2026, it reported net sales of 149 Cr and a net profit of 13 Cr.

Overview: <BR>NGL Fine-Chem Limited is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.<BR><BR>History: <BR>NGL Fine-Chem Limited was incorporated on December 18, 1981, initially as a Private Limited Company in Maharashtra, and later became a Public Limited Company. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 149 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 13 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,757 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 35.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.06% <BR>Debt-Equity: 0.20 <BR>Return on Equity: 14.59% <BR>Price to Book: 5.29<BR><BR>Contact Details: <BR>Address: 301 E Square Subhash Road, Vile Parle (East) Mumbai Maharashtra : 400057 <BR>Tel: +91-22-2663 6450 <BR>Email: cs@nglfinechem.com / info@nglfinechem.com <BR>Website: http://www.nglfinechem.com

Are NGL Fine Chem Ltd latest results good or bad?

NGL Fine Chem Ltd's latest results show strong revenue growth of 57.13% year-on-year, reaching ₹149.23 crores, but profitability concerns arise with a 14.02% sequential decline in net profit and decreased operating margins. While revenue growth is positive, the mixed results highlight challenges in sustaining profitability.

NGL Fine Chem Ltd's latest results present a mixed picture. On one hand, the company achieved impressive revenue growth, with net sales increasing by 57.13% year-on-year to ₹149.23 crores in Q4 FY26. This marks the highest quarterly revenue in the company's history, reflecting strong demand for its pharmaceutical intermediates and active pharmaceutical ingredients.<BR><BR>However, profitability metrics indicate some concerns. While net profit surged dramatically by 2,398% year-on-year to ₹13.49 crores, there was a sequential decline of 14.02% from the previous quarter. This raises questions about the sustainability of profit levels, especially as operating margins decreased to 14.35% from 17.50% in the prior quarter. The PAT margin also fell to 9.04%, down from 12.30%.<BR><BR>Overall, while the revenue growth is a positive sign, the declining profitability and margin pressures suggest that the company faces operational challenges that need to be addressed. Investors are optimistic, as reflected in the stock's recent surge, but the mixed results warrant careful consideration regarding the company's ability to maintain its growth trajectory and improve profitability moving forward.

Is NGL Fine Chem technically bullish or bearish?

As of December 3, 2025, the trend has shifted to mildly bearish due to bearish signals from MACD, KST, Bollinger Bands, and Dow Theory, despite daily moving averages remaining mildly bullish.

As of 3 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by weekly MACD and KST indicators both showing mild bearishness, alongside bearish signals from Bollinger Bands and Dow Theory on a weekly basis. The daily moving averages remain mildly bullish, but the overall trend indicates weakness. The stock has underperformed significantly over the past month and year compared to the Sensex, reinforcing the bearish outlook.

How has been the historical performance of NGL Fine Chem?

NGL Fine Chem has shown an upward trend in net sales and total assets from Mar'20 to Mar'25, increasing from 151.69 Cr to 368.26 Cr, but profitability has declined, with profit after tax dropping from 56.72 Cr in Mar'21 to 21.12 Cr in Mar'25. Overall, while sales and assets have grown, the company faces challenges in maintaining profitability.

Answer:<BR>The historical performance of NGL Fine Chem shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>NGL Fine Chem's net sales have shown a general upward trend, increasing from 151.69 Cr in Mar'20 to 368.26 Cr in Mar'25, despite a dip in Mar'22. Total operating income followed a similar pattern, reaching 368.26 Cr in Mar'25. The raw material cost has also risen significantly, from 69.75 Cr in Mar'20 to 182.41 Cr in Mar'25, contributing to total expenditure growth from 132.30 Cr in Mar'20 to 334.39 Cr in Mar'25. Operating profit (PBDIT) peaked at 87.76 Cr in Mar'21 but has since declined to 42.50 Cr in Mar'25. Profit before tax mirrored this trend, decreasing from 77.59 Cr in Mar'21 to 27.71 Cr in Mar'25. Profit after tax also saw fluctuations, with a high of 56.72 Cr in Mar'21 and a drop to 21.12 Cr in Mar'25. The company's total liabilities increased from 153.62 Cr in Mar'20 to 433.39 Cr in Mar'25, while total assets rose from 153.62 Cr to 433.39 Cr in the same period. Cash flow from operating activities improved to 35.00 Cr in Mar'25, while net cash inflow/outflow remained stable at 0.00 Cr. Overall, NGL Fine Chem has experienced growth in sales and assets, but profitability has faced challenges in recent years.

When is the next results date for NGL Fine Chem?

The next results date for NGL Fine Chem is 12 November 2025.

The next results date for NGL Fine Chem is scheduled for 12 November 2025.

Is NGL Fine Chem overvalued or undervalued?

As of August 4, 2025, NGL Fine Chem is considered overvalued with a PE ratio of 38.04, an EV to EBITDA ratio of 23.60, and a Price to Book Value of 2.81, significantly higher than its peers, while also showing a year-to-date return of -28.62%, lagging behind the Sensex's 3.69%.

As of 4 August 2025, the valuation grade for NGL Fine Chem has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 38.04, an EV to EBITDA ratio of 23.60, and a Price to Book Value of 2.81. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, NGL Fine Chem's PE ratio is higher than Sun Pharma's 34.25 and significantly above Cipla's attractive PE of 22.7. The PEG ratio for NGL Fine Chem is notably low at 0.00, indicating a lack of growth expectations, which further supports the overvaluation claim. Additionally, while the stock has shown strong returns over the long term, its recent performance has lagged behind the Sensex, with a year-to-date return of -28.62% compared to the Sensex's 3.69%.

Who are the top shareholders of the NGL Fine Chem?

The top shareholder of NGL Fine Chem is Rajesh Lawande, holding 21.89%, with no pledged promoter holdings. Public shareholders include Yashkumar Poonamchand Golechha at 1.05%, while individual investors collectively hold 22.75%; mutual funds and foreign institutional investors have negligible holdings.

The top shareholders of NGL Fine Chem primarily include the promoters, with Rajesh Lawande holding the largest share at 21.89%. There are no pledged promoter holdings. In terms of public shareholders, Yashkumar Poonamchand Golechha is the highest individual shareholder at 1.05%. Additionally, individual investors collectively hold 22.75% of the company's shares. Mutual funds and foreign institutional investors have minimal holdings, with mutual funds holding 0.0% and only one foreign institutional investor also holding 0.0%.

Has NGL Fine Chem declared dividend?

NGL Fine Chem Ltd has declared a 35% dividend, amounting to ₹1.75 per share, with an ex-date of August 16, 2024. While recent total returns have been negative, the company has shown significant positive returns over the past five years.

NGL Fine Chem Ltd has declared a 35% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 1.75<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 0.17%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -42.05%, with a dividend return of 0%, resulting in a total return of -42.05%.<BR><BR>Over the 1 year period, the price return was -53.0%, accompanied by a dividend return of 0.07%, leading to a total return of -52.93%.<BR><BR>For the 2 years period, the price return was -27.5%, with a dividend return of 0.21%, culminating in a total return of -27.29%.<BR><BR>In the 3 years period, the price return was -41.37%, and the dividend return was 0.21%, resulting in a total return of -41.16%.<BR><BR>During the 4 years period, the price return was -44.93%, with a dividend return of 0.34%, leading to a total return of -44.59%.<BR><BR>In the 5 years period, the price return was 163.89%, accompanied by a dividend return of 2.62%, resulting in a total return of 166.51%.<BR><BR>Overall, while NGL Fine Chem has declared a dividend, the total returns over the shorter periods have been negative, indicating a challenging performance. However, the longer-term returns over five years show a significant positive return, suggesting potential recovery or growth in the future.